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Abstract
The Sleep and Pain Diathesis (SAPD) Model predicts that sleep quality is related to Fibromylagia
(FM) outcomes such as disability and depression and that these relationships are mediated by both
pain and impaired emotional dysregulation. The purpose of this paper is to provide a preliminary
test of this model using cross-sectional data. 35 adult women, who had been living with FM for an
average of 13 years, completed a battery of questionnaires that included reports of pain, sleep,
affect, and disability. Consistent with this model, FM patients who reported more disrupted sleep
also reported higher levels of psychological disability (i.e., BDI depression symptoms) and
physical disability. Moreover, the trajectory of the relationship between sleep and pain appears to
be mediated by cognitive processes such as increased pain helplessness and, thus, the relationship
between sleep and disability appears to be mediated via pain. These data are consistent with the
SAPD model, and lend support for the need to include sleep related factors as a critical contributor
to our understanding of FM.
Fibromyalgia (FM) is a chronic pain condition that affects close to 2% of the general
population (F. Wolfe, Ross, Anderson, Russell, & Hebert, 1995). Although the symptom
profile of FM is well understood to include widespread, intense pain combined with extreme
fatigue, poor sleep quality, gastrointestinal complaints, cognitive deficits, and depression
(e.g., Bennett, Jones, Turk, Russell, & Matallana, 2007; F. Wolfe et al., 2000; F Wolfe &
Skevington, 2000), little is known about the etiology of the disorder. Pain is often the most
salient symptom of FM and thus FM has traditionally been conceptualized as a pain
disorder, with other somatic symptoms (e.g., fatigue, sleep problems) conceptualized as
downstream of pain. However, the Sleep and Pain Diathesis (SAPD) model would suggest
that for many patients with FM, sleep should be modeled upstream, as an etiological factor
and also a “driving force” activating a cognitive feedback loop that serves to maintain a
broad range of FM symptoms. The purpose of this paper is to provide a preliminary test of
this model using cross-sectional data.
FM has traditionally been treated as a pain disorder. However this approach has failed to
yield effective treatment outcomes. One of the largest studies of Rheumatology clinic FM
patients found that FM patients were frequent users of health care services (an average of 10
health care visits per year), but did not show improvements in symptoms over time (F.
Wolfe et al., 1997a; F. Wolfe et al., 1997b). Moreover, there is ample evidence that
analgesics and opiate pain medications that are efficacious for management of other pain
disorders do not improve functioning in FM patients. Antidepressant medications have
proven to provide improvement in symptoms, but the most robust effect sizes are found
using tri-cyclic antidepressants, a class of antidepressants that also improve sleep (Hauser,
Bernardy, Uceyler, & Sommer, 2009). Clearly, there is a need for greater understanding of
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the functional interaction between the symptoms that makeup this disorder in order to
inform more effective treatment options for FM.
Although sleep disruption is not among the core diagnostic symptoms of FM (F. Wolfe et
al., 1990), FM patients almost always report disrupted sleep (e.g.,White, Speechley, Harth,
& Ostbye, 1999) and unlike pain symptoms, multiple facets of the disrupted sleep have been
routinely, throughly documented. For instance, FM patients have been found to have an
EEG abnormality (known as alpha-delta sleep) that correlates with fatigue and achiness
(Moldofsky & Scarisbrick, 1976; Moldofsky, Scarisbrick, & England, 1975) (e.g.,A. Drewes
et al., 1995; A. M. Drewes et al., 1995; Roizenblatt, Moldofsky, Benedito-Silva, & Tufik,
2001), a high frequency of arousals (Jennum, Drewes, Andreasen, & Nielsen, 1993; Kooh et
al., 2003; Rizzi et al., 2003; Sergi et al., 1999), more light sleep (Rizzi et al., 2003;
Roizenblatt et al., 2001; Shaver, Lentz, Heitkemper, Buchwald, & Woods, 1997), less deep,
slow-wave sleep (Rizzi et al., 2003), and more fragmented sleep (Shaver et al., 1997). In
addition, FM patients show a high prevalence of sleep disorders such as Obstructive Sleep
Apnea (OSA) (May, West, Baker, & Everett, 1993; Shah, Feingberg, & Krishnan, 2006), a
less severe form of respiratory related sleep problem, Upper Airway Resistant Syndrome
(UARS) (A. Gold, Dipalo, Gold, & O'Hearn, 2003), Restless Leg Syndrome (RLS) (Yunus
& Aldag, 1996), and Periodic Limb Movements (PLM) (Tayag-Kier et al., 2000). As
suggested by this review, not all FM patients have one specific type of sleep problem, rather
across studies of FM patients we see a heterogeneous constellation of problems that are
more generally experienced as “non-refreshing sleep.”
The SAPD model is an attempt to specify a common causal trajectory of FM using a
diathesis-stress formulation that begins with sleep disruption. This model proposes that a
wide range of biopsychosocial stressors can set the stage for FM by activating diatheses for
sleep disruption. Sleep disruption, in those most sensitive to pain, then initiates a cascade of
symptoms, including pain and fatigue. Once this process is initiated, the symptoms of FM
are perpetuated and aggravated by cognitive variables such as vigilance and perceptions of
helplessness that increase perceptions of threat to a broad range of stimuli. These threat
related schema would also be expected to manifest in diminished emotion regulation. Final
endpoints for patients with FM are known to include disability and elevated levels of
depression symptoms, if not clinical depression. Note that the SAPD model does not claim
to provide an etiological model for ALL patients with FM. We do however argue that onset
of chronic sleep disruption is sufficient in those with low pain tolerance to account for the
symptom profile that is described as FM.
The purpose of the present study was to evaluate preliminary evidence for the role of sleep
in FM. The SAPD model would be supported if sleep were related to FM outcomes such as
disability and depression and if those relationships were mediated by pain and by emotional
dysregulation. Although we have imposed a specific causal trajectory on these data, it
should be noted that treatment studies and prospective longitudinal data will be needed to
disconfirm these causal models.
Method
Participants
Participants were part of two ongoing projects designed to investigate the relationship
between sleep and FM symptoms. Sleep Neuroscience Affect and Pain (Project SNAP)
participants were community members recruited either in-person at community events,
through advertisements in the university newspaper, or through referral from friends.
Participants were included if they had a physician diagnosis of FM, and did not have a
history of cancer, autoimmune illness, or head injury that resulted in unconsciousness.
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Fibromyalgia and Sleep Treatment (Project FAST) were recruited mainly from physician
referral, through the study's in-person recruitment at the hospital's rheumatology clinic, and
through online advertising. Project FAST is an NIH clinical trial of a sleep treatment for
patients with FM and a comorbid sleep disorder. Participants were screened out if they had a
comorbid autoimmune illness or significant history of another chronic pain condition. Data
used here were pre-treatment and collected from the initial participant questionnaire.
Measures
Participants in both studies completed a battery of questionnaires that included reports of
pain, sleep, affect, and disability.
McGill Pain Questionnaire, short form (MPQ-S). The MPQ-S is a shortened version of the
original MPQ-long from. Participants rate a list of 15 descriptors of pain on a Likert scale
ranging from 0 (no pain) – 3 (severe pain). Scores on items are averaged to produce two
subscales: 15 adjectives comprise the sensory dimension (e.g., throbbing, stabbing) and four
adjectives comprise the affective dimension (e.g., cruel-punishing) of pain experience
(Melzack, 1987). Correlations between the short and long forms ranged between 0.67 and
0.87 and Internal consistency reliability was 0.73 to 0.89 in repeated testing of rheumatoid
arthritis and fibromyalgia patients (Burckhardt, 1994).
Pittsburgh Sleep Quality Inventory (PSQI). The PSQI is a self-report questionnaire that
retrospectively assesses sleep quality and frequency of sleep disruptions from a one-month
period. The measure is comprised of 14 multiple-choice items and 5 open-ended items that
are rated from 0 (“No difficulty”) to 3 (“Severe difficulty”). Seven composite scores are
derived from these responses to yield a total global score. Composite score areas include:
sleep quality, latency, duration and disturbances, habitual sleep efficiency, daytime
dysfunction, and use of sleep medication. An optional 5 questions can be asked of the
spouse or housemate on sleep habits to contribute to the overall clinical picture but do not
additively contribute to the global score (Bussye, Reynolds, Monk, Berman, & Kupfer,
1989). Good to excellent construct and content validity have been reported, as well as high
internal consistency (α = .83), and excellent treatment sensitivity (Hunsley & Mash, 2008).
Fibromyalgia Health Assessment Questionnaire (FHAQ). FM related disability was assessed
via the FHAQ. Items from the FHAQ were drawn from the Health Assessment
Questionnaire (Fries, Spitz, Kraines, & Holman, 1980) and revised to fit the symptom
profile of FM. The FHAQ was developed as an internally consistent alternative to other
functional disability measures such as the Fibromyalgia Impact Questionnaire (Burckhardt,
Clark, & Bennett, 1991) that were found to underestimate disability in individuals with FM
(F. Wolfe et al., 2000).
Beck Depression Inventory (BDI). The BDI-II (Beck, Steer & Brown, 1996) assesses 21
symptoms of depression relative to the DSM-IV diagnostic criteria. Symptoms include
sadness, pessimism, past failure, loss of pleasure, guilty feelings, punishment feelings, self-
dislike, self-criticalness, suicidal thoughts or wishes, crying, loss of interest, indecisiveness,
changes in sleeping pattern, irritability, changes in appetite, tiredness or fatigue, loss of
interest in sex, agitation, worthlessness, and concentration difficulty. Symptoms are
measured on a 4 point scale with range of 0 –3. Scores 13 and above are indicative of high
risk for depression. Scores 12 or below are at lower risk for depression. Psychometrics of the
BDI-II were generated from a sample of 500 psychiatric outpatients (alpha = .92) and a
sample of 120 college students (apha = .93) (Beck, Steer, & Brown, 1996). Dozois, Dobson,
and Ahnberg (1998) examined the sensitivity and specificity of the BDI-II in a sample of
1,022 college students and found .81 and .92, respectively.
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Rheumatology Attitudes Index (RAI). Pain helplessness was assessed using the helplessness
items from the RAI (Callahan, Brooks, & Pincus, 1988; Nicassio, Wallston, Callahan,
Herbert, & Pincus, 1985). Items from the RAI were drawn from the Arthritis Helplessness
Index and revised to fit the symptom profile of FM. The RAI helplessness subscale has been
found to have adequate internal consistency and has been found to have stronger correlations
with measures of functional distress than the full RAI (Callahan et al., 1988; Nicassio et al.,
1985).
The Emotion Amplification and Reduction Scales (TEARS). The TEARS is an 18-item self-
report questionnaire that assesses perceived ability to change the trajectory of an emotional
response through amplification or reduction (Hamilton, Karoly, Gallagher, Stevens, Karlson,
& McCurdy, 2007). The TEARS has been found to correlate with well-established
measures, such as the Positive and Negative Affect Schedule (PANAS; Watson, Clark, &
Tellegen, 1988) and the Beck Depression Inventory (BDI; Beck & Steer, 1993). TEARS-
Amplification is correlated with higher PANAS-Positive Affect (β = .34, p < .05) and
TEARS-Reduction is correlated with PANAS-Negative Affect (β = −.36, p <.05) and BDI
total score (β = −.15, p < .05). Hamilton et al., demonstrated that both scales have internal
consistency ratings that exceed .80.
Data analysis and Results
Participants were 35 adult women, who had been living with FM for an average of 13.02
years (SD = 9.18). Participants exceeded clinical cut-offs for PSQI sleep (M=13.91) and
BDI depression symptoms (M=16.86). Table 1 contains demographic data. Table 2 contains
a correlation matrix that includes relevant predictors and possible covariates.
Data Analytic Strategy. Data were analyzed using Ordinary Least Squares Regression
(OLS). Zero order correlations were examined to identify potential covariates and to
determine whether the necessary preconditions for testing mediation were present in the data
(Baron & Kenny, 1986). Multiple Imputation (using 10 model iterations) was used to adjust
for missing data. A total of 14 data points were missing, meaning that 4% of the data shown
in Table 2 were imputed. Note that correlations between the RAI and other variables are
based solely on the FAST data (N=22).
Zero order correlations were examined for possible covariates and to determine whether it
would be appropriate to test the meditational models specified by the SAPD model (Table
2). The potential covariates, age and years with FM were correlated only with sensory pain.
Although years with pain was correlated with MPQ sensory pain, when included with other
predictors years with pain was no longer significant and did not substantially change the
results reported in Tables 3 and 4. The conditions to test the hypothesis that pain mediated
the relationship between sleep and outcome variables (disability and depression) were met.
1) The predictor, PSQI sleep was correlated with the outcomes of interest, BDI depression
symptoms and FHAQ disability. 2) The mediating variables pain (MPQ affective pain and
MPQ sensory pain) were correlated with BDI depression symptoms and FHAQ disability. 3)
Finally, both MPQ subscales were correlated with PSQI sleep. Thus, tests of mediation
included pain and emotion amplification as mediators of the relationship between PSQI
sleep disruption and the outcomes depression symptoms and disability. The two TEARS
subscales were not related to sleep and, thus, were not tested as mediators. However, the
TEARS-reduction (TEARS red)subscale was correlated with depression symptoms and was,
thus, included as a predictor.
Predictions made by the SAPD model were tested using OLS regression. Specifically, the
SAPD model predicts that sleep disruption will be associated with significantly higher pain
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(shown in Table 2) and that pain will be associated with outcomes such as disability and
depression. As can be seen in Table 3, PSQI sleep problems were related to higher levels of
BDI depression symptoms. Note that values presented in the table are averages of 10
imputations used to replace missing data. Ranges of imputed values are presented in text.
Sleep problems alone accounted for an estimated 20% (range: r2Δ =.17 to .26) of variance in
BDI depression symptoms, F(1,33) 9.00, p<.02. Thus, every 1 unit increase in PSQI sleep
correlated with nearly a two point increase in BDI depression symptoms (b's range 1.47–
1.93). In the next step, we added MPQ sensory (b's all ns) and MPQ affective dimensions of
pain (b's range 8.82–10.73), accounting for an estimated 48% (range: r2Δ =.45 to .52) of
depression symptoms, F(2,31) 23.62, p<.00. Thus, every one unit increase in affective pain
corresponded to a higher BDI depression symptom scores of approximately 10 points.
Adding pain ratings mediated the effect of sleep on BDI depression symptoms (Sobel
=2.669, p<.05). Finally, TEARS red (b's range −2.87 to −5.03), accounted for an additional
7% (range: r2Δ =.04 to .11) of the variance in BDI depression symptoms, F(1,30) 9.82, p<.
05. In contrast to the negative predictors, for every one unit increase in the TEARS red
(representing the ability to reduce negative emotions) was correlated with a four unit
reduction in the BDI depression symptom score. Collectively, these data accounted for the
majority of variance in depression scores r2 total=.73 (range .68–.80), F(4,30) 24.69, p<.00.
A similar pattern of effects was found for FHAQ disability. There were no missing data in
these equations. Thus, data in the table reflect observed, non-bootstrapped estimates of the
observed relationships. PSQI sleep accounted for 30% of the variance in FHAQ disability
(range: r2Δ =.27 to .31), F(1,33) 14.22, p<.00. Adding the MPQ sensory and MPQ affective
pain accounted for an additional 27% (range: r2Δ =.26 to .9), F(2,31) 9.49 p<.00 and
partially moderated the effect of PSQI sleep on FHAQ disability. Similar to the BDI, poor
sleep was related to a greater degree of disability and at least part of that relationship was
accounted for by higher ratings of affective pain (Sobel=2.745, p<.01).
Finally, we investigated the relationship between PSQI sleep and MPQ pain (Table 4) and
whether this relationship was mediated by RAI helplessness. The SAPD model predicts that
sleep disruption will be related to increased pain, in part because sleep disruption is
associated with dysfunctional cognitions about the ability to cope with pain. RAI pain-
helplessness was available only in the FAST data. Thus, this hypothesis was tested in this
smaller data set (N=23). Consistent with these predictions PSQI sleep disruption was related
to MPQ sensory pain, with sleep disruption accounting for 22% of the variance, F(1,22)
7.004, p=.02. In the second step of this model we added RAI pain helplessness, which
accounted for an additional 20% of the variance in MPQ sensory pain F(1,22) 6.835, p=.02.
These two measures in total accounted for 46% of the variance in MPQ sensory pain F(2,22)
7.941, p=.003. Adding pain helplessness to the model significantly attenuated the
relationship between PSQI sleep disruption and sensory pain (Sobel=2.367, p<.01), so that
after adding RAI pain-helplessness, PSQI sleep was only a marginally significant predictor
of MPQ affective pain F(1,23) 2.84, p=.10. RAI helplessness, however accounted for a
significant amount of variance in MPQ affective pain F(1,23) 19.71, p=.00. Collectively
these variables accounted for 53% of the variance in MPQ affective pain. These data suggest
that the effect of sleep disruption on pain was substantially determined by cognitive factors
such as the biased appraisal that one cannot manage pain.
Discussion
FM may best be conceptualized as an endophenotype, or a constellation of symptoms that
may result from multiple causes. The SAPD model is an attempt to capture one causal
trajectory. Consistent with this model, FM patients who reported more disrupted sleep also
reported higher levels of psychological disability (i.e., BDI depression symptoms) and
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physical disability. Moreover, the trajectory of the relationship between sleep and pain
appears to be mediated by cognitive processes such as increased pain helplessness and, thus,
the relationship between sleep and disability appears to be mediated via pain. These data are
consistent with the SAPD model, and lend support for the need to include sleep related
factors as a critical contributor to our understanding of FM.
From a clinical perspective, it is difficult to treat FM. Patients present with relatively severe
levels of disability, but without obvious markers of pathology. Moreover, outcome
trajectories are unclear. Recently, longitudinal data from 1555 FM patients showed that over
the course of 10 years, most patients experienced fluctuation in symptom severity, 35–40%
of patients steadily worsened, and only 25% improve steadily over time (Walitt et al., 2011).
Lack of a clear symptom trajectory combined with the absence of objective metabolic and
physical markers with FM are likely to enhance perceptions that the disease is mysterious
(Reich, Johnson, Zautra, & Davis, 2006), and that effective coping is not possible (Johnson,
Zautra, & Davis, 2006). Coping may be particularly problematic for individuals with the
worst quality of sleep and for any individual on days following a night of disturbed sleep
because of general effects of fatigue, but also because chronic sleep problems are associated
with increased arousal and vigilance (Espie, Broomfield, MacMahon, Macphee, & Taylor,
2006).
Consistent with this hypothesis are theories of both FM (Turk, 2002) and insomnia
(Spielman, Caruso, & Glovinsky, 1987) that emphasize that attention to symptoms maintain
and exacerbate perceptions of symptom severity. This is a very reasonable assertion given
that normally functioning attention mechanisms have evolved to help shift cognitive
resources to stimuli in ourselves and in our environment that might represent threat to our
well being. This early threat detection system has been labeled the “motivated attention
network” by researchers of neuroaffect and neurocognition (for a description of model of
motivated attention see Bradley, Codispoti, Cuthbert, & Lang, 2001). In short it is argued
that the motivated attention system, which is controlled by early, posterior attention and
limbic system structures, is designed to allow for biased detection of highly arousing and
negative internal and external stimuli. This type of bias is argued to be primarily
involuntary, normal, and often desirable. In fact this biased attention plays an important
evolutionary role because it allows for early detection of threatening stimuli and it allows for
the early activation of response plans which might help us to avoid serious injury or trauma
(Bradley et al., 2001). Pain and fatigue act as clear, internally-localized signals of threat to
our physical selves, which capture attentional resources leaving positive and neutral stimuli
relatively ignored.
A perfect example of this role of motivated attention in FM is the phenomena of symptom
vigilance which might exacerbate pain helplessness (as measured in the current study). Two
fMRI studies have now shown that FM patients do not differ qualitatively from healthy
adults in their response to stimuli that both groups categorize as clearly painful. However,
unlike the healthy adults, FM patients show a similar pattern of response across
neuroanatomical structures associate with motivated attention that is matched to perceived
pain intensity rather than actual stimulus intensity (e.g., Cook et al., 2004; Gracely, Petzke,
Wolfe, & Clauw, 2002). Thus, the neurophysiological experience of pain in FM patients is
clearly more subjective.
Furthermore, unlike healthy controls, FM patients show a heightened response to non-
painful levels of blunt thumb nail bed pressure (Gracely et al., 2002) and heat stimuli (Cook
et al., 2004). These kinds of stimuli would better be characterized as threatening rather then
painful, and they capture greater motivated attention in patients with FM. Vigilance to
negative stimuli in general may explain how low-level aches and pains normally associated
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with chronic sleep deprivation could activate pain processing centers that are not normally
activated by such low intensity stimuli. Furthermore, this experience of more consistent
perceived pain, again, likely increases feelings of helplessness. Symptom vigilance may also
partially explain the lack of treatment efficacy in FM. A recent meta-analysis of FM-
medication trials showed that FM patients have a higher rate of “nocebo-response” (mening
placebo patients reporting adverse events similar to side effects of the active medication
such as nausea, insomnia, fatigue, headache) than drug trials for migraine medications and
Multiple Sclerosis medications (Mitskiostas, Chalarakis, Mantonakis, Delicha, & Sfikakis,
2011)
It should be noted that there are significant limitations to our findings. First and foremost,
these are cross sectional data. In order to test the SAPD model, it will be necessary to
examine waxing and waning of sleep and pain over time. Although the SAPD model
predicts that sleep is the primary driving force in the relationship between sleep and pain, in
day to day practice we expect for the relationship to be bidirectional (Affleck, Urrows,
Tennen, Higgins, Abeles, et al., 1996). However, the SAPD model goes further than
postulating that sleep is driving symptoms of FM. The SAPD model suggests that sleep
disruption activates a cognitive schema that activates our motivated attention system and,
thus, promotes vigilance to threat related stimuli and amplifies the perceived threat and/or
pain value of existing negative stimuli. Again, it will be necessary to examine state related
changes in motived attention to determine whether it is sleep or pain that drives increased
threat processing.
Is sleep upstream of pain? Is there a bidirectional relationship between sleep and pain? Or
does pain drive sleep disruption? There are certainly data to support each of these assertions.
However, this is more than an academic-scientific argument. Approaching FM as though it
were a pain disorder has provided only partial relief to patients with FM (e.g., Walitt et al.,
2011). If the clinical community were to act on the hypothesis that sleep disruption is
upstream, then this new understanding opens additional avenues of intervention. As noted in
this special issue, there are well validated interventions for sleep disorders like insomnia.
Moreover, behavioral interventions for insomnia have been shown to produce benefits for
FM patients (Edinger, Wohlgemuth, Krystal, & Rick, 2005) and treatment of respiratory
related sleep disorders have produced marked improvements in FM symptoms such as pain
and fatigue (Gold, Dipalo, Gold, & Broderick, 2004). Thus, attending to the role of sleep in
FM may well offer concrete treatment benefits to a class of patients who have treatment
options with limited efficacy.
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Table 1
Demographics
FAST (N=23) SNAP (N=12) Combined (N=35)
Age M = 45.97 (SD = 10.49) M = 49.00 (SD = 10.60) M = 47.08 (SD = 10.47)
Ethnicity 61.9% Caucasian 91% Caucasian, 72.7% Caucasian
28% African-American 8.3% African-American 21.2% African-American
8% Hispanic 6.1% Hispanic
8% missing 5.7% Missing
Years with Pain M = 11.38 (SD = 8.99) M = 15.87 (SD = 9.19) M = 13.02 (SD = 9.18)
Marital 65.22% married 58.3% married 62.86% married
Status 17.39% divorced 33.3% divorced 22.86% divorced
17.39% single 8.3% single 14.28% single
Annual Income M = $40,000–59,000 M = $60,000–79,999
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Table 3
Sleep, Pain, and Emotion Regulation Predict Symptoms of FM
Depression Symptoms b SE t R2Δ
Set 1 (Constant) −7.061 8.411 −.839
PSQI 1.720 .594 2.896** .17*
Set 2 (Constant) −2.919 5.804 −.503
PSQI .568 .454 1.253
MPQ Sensory −1.227 2.508 −.489
MPQ Affective 10.506 1.879 5.591** .48**
Set 3 (Constant) 8.039 6.472 1.242
PSQI .393 .404 .973
MPQ Sensory −.080 2.267 −.035
MPQ Affective 9.207 1.736 5.304**
TEARS red −3.894 1.509 −2.581** .07*
Disability Symptoms b SE t R2Δ
Step 1 (Constant) .519 .280 1.855
PSQI .075 .020 3.812** .306**
Step 2 (Constant) .602 .229 2.627
PSQI .035 .019 1.883†
MPQ Sensory .152 .106 1.436
MPQ Affect .185 .081 2.285** .264**
Note:
Note: PSQI=Pittsburgh Sleep Quality Inventory, MPQ S and A=Multidimensional Pain Questionnaire, Sensory and Affective Dimension,
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Table 4
Sleep and Helplessness predict Pain
Sensory Pain b SE t R2Δ
Step 1 (Constant) .269 .568 .474
PSQI .102 .039 2.647** .259
Step 2 (Constant) −.286 .543 −.527
PSQI .044 .041 1.086
RAI .362 .139 2.614** .196
Affective Pain b SE t R2Δ
Step 1 (Constant) .169 .875 .194
PSQI .100 .059 1.686† .124
Step 2 (Constant) −1.018 .683 −1.489
PSQI −.024 .051 −.468
RAI .775 .174 4.440** .446
Note:
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